A Toolbox Approach to Obesity Treatment in Urban Safety-Net Primary Care Clinics: a Pragmatic Clinical Trial.


Journal

Journal of general internal medicine
ISSN: 1525-1497
Titre abrégé: J Gen Intern Med
Pays: United States
ID NLM: 8605834

Informations de publication

Date de publication:
11 2019
Historique:
received: 23 04 2018
accepted: 26 06 2019
revised: 04 12 2018
pubmed: 6 9 2019
medline: 18 11 2020
entrez: 6 9 2019
Statut: ppublish

Résumé

There is a need for new strategies to improve the success of obesity treatment within the primary care setting. To determine if patients offered low out-of-pocket cost weight management tools achieved more weight loss compared to usual care. Twelve-month pragmatic clinical weight loss trial with a registry-based comparator group performed in primary care clinics of an urban safety-net hospital. From a large clinical registry, we randomly selected 428 patients to have the opportunity to receive the intervention. Medical weight management tools-partial meal replacements, recreation center vouchers, pharmacotherapy, commercial weight loss program vouchers, and a group behavioral weight loss program-for $5 or $10 monthly. Patients chose their tools, could switch tools, and could add a second tool at 6 months. The primary outcome was the proportion of intervention-eligible patients who achieved ≥ 5% weight loss. The main secondary outcome was the proportion of on-treatment patients who achieved ≥ 5% weight loss. Overall, 71.3% (305 of 428) had available weight measurement data/PCP visit data to observe the primary outcome. At 12 months, 23.3% (71 of 305) of intervention-eligible participants and 15.7% (415 of 2640) of registry-based comparators had achieved 5% weight loss (p < 0.001). Of the on-treatment participants, 34.5% (39 of 113) achieved 5% weight loss. Mean percentage weight loss was - 3.15% ± 6.41% for on-treatment participants and - 0.30% ± 6.10% for comparators (p < 0.001). The initially preferred tools were meal replacements, pharmacotherapy, and recreation center passes. Access to a variety of low out-of-pocket cost weight management tools within primary care resulted in ≥ 5% body weight loss in approximately one quarter of low-income patients with obesity. https://clinicaltrials.gov/ct2/show/NCT01922934.

Sections du résumé

BACKGROUND
There is a need for new strategies to improve the success of obesity treatment within the primary care setting.
OBJECTIVE
To determine if patients offered low out-of-pocket cost weight management tools achieved more weight loss compared to usual care.
DESIGN
Twelve-month pragmatic clinical weight loss trial with a registry-based comparator group performed in primary care clinics of an urban safety-net hospital.
PARTICIPANTS
From a large clinical registry, we randomly selected 428 patients to have the opportunity to receive the intervention.
INTERVENTIONS
Medical weight management tools-partial meal replacements, recreation center vouchers, pharmacotherapy, commercial weight loss program vouchers, and a group behavioral weight loss program-for $5 or $10 monthly. Patients chose their tools, could switch tools, and could add a second tool at 6 months.
MAIN MEASURES
The primary outcome was the proportion of intervention-eligible patients who achieved ≥ 5% weight loss. The main secondary outcome was the proportion of on-treatment patients who achieved ≥ 5% weight loss.
KEY RESULTS
Overall, 71.3% (305 of 428) had available weight measurement data/PCP visit data to observe the primary outcome. At 12 months, 23.3% (71 of 305) of intervention-eligible participants and 15.7% (415 of 2640) of registry-based comparators had achieved 5% weight loss (p < 0.001). Of the on-treatment participants, 34.5% (39 of 113) achieved 5% weight loss. Mean percentage weight loss was - 3.15% ± 6.41% for on-treatment participants and - 0.30% ± 6.10% for comparators (p < 0.001). The initially preferred tools were meal replacements, pharmacotherapy, and recreation center passes.
CONCLUSIONS
Access to a variety of low out-of-pocket cost weight management tools within primary care resulted in ≥ 5% body weight loss in approximately one quarter of low-income patients with obesity.
TRIAL REGISTRATION
https://clinicaltrials.gov/ct2/show/NCT01922934.

Identifiants

pubmed: 31485965
doi: 10.1007/s11606-019-05222-0
pii: 10.1007/s11606-019-05222-0
pmc: PMC6848318
doi:

Banques de données

ClinicalTrials.gov
['NCT01922934']

Types de publication

Journal Article Pragmatic Clinical Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2405-2413

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK048520
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001082
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007446
Pays : United States

Références

Control Clin Trials. 2003 Oct;24(5):610-28
pubmed: 14500058
Lancet. 2011 Apr 16;377(9774):1341-52
pubmed: 21481449
Arch Intern Med. 2012 Apr 9;172(7):565-74
pubmed: 22412073
Arch Intern Med. 2001 Jan 22;161(2):218-27
pubmed: 11176735
Diabetes Care. 2016 Aug;39(8):1345-55
pubmed: 27271190
Med Care. 2013 Feb;51(2):186-92
pubmed: 23047128
JAMA. 2014 Nov 5;312(17):1779-91
pubmed: 25369490
N Engl J Med. 2005 Nov 17;353(20):2111-20
pubmed: 16291981
N Engl J Med. 1999 Aug 5;341(6):427-34
pubmed: 10432328
Endocr Pract. 2016 Jul;22 Suppl 3:1-203
pubmed: 27219496
N Engl J Med. 2011 Nov 24;365(21):1959-68
pubmed: 22085317
JAMA. 2018 Apr 24;319(16):1723-1725
pubmed: 29570750
Int J Obes Relat Metab Disord. 2003 May;27(5):537-49
pubmed: 12704397
N Engl J Med. 2013 Jul 11;369(2):145-54
pubmed: 23796131
N Engl J Med. 2011 Nov 24;365(21):1969-79
pubmed: 22082239
J Clin Oncol. 2014 Nov 1;32(31):3568-74
pubmed: 25273035
Obesity (Silver Spring). 2009 Apr;17(4):713-22
pubmed: 19180071
Obesity (Silver Spring). 2014 Jul;22 Suppl 2:S41-410
pubmed: 24227637
J Clin Endocrinol Metab. 2015 Feb;100(2):342-62
pubmed: 25590212
N Engl J Med. 2012 Mar 29;366(13):1209-17
pubmed: 22455415
J Am Board Fam Med. 2009 Mar-Apr;22(2):115-22
pubmed: 19264934
Int J Obes (Lond). 2013 May;37(5):751-3
pubmed: 22777541
Prev Med Rep. 2016 Jun 30;4:296-302
pubmed: 27486558
Lancet Diabetes Endocrinol. 2016 Nov;4(11):913-921
pubmed: 27595918

Auteurs

David R Saxon (DR)

Division of Endocrinology, Metabolism and Diabetes, University of Colorado School of Medicine, Aurora, CO, USA. david.saxon@ucdenver.edu.
Denver/Seattle Center of Innovation for Veteran-Centered and Values Driven Care, VA Eastern Colorado Health Care System, Denver, CO, USA. david.saxon@ucdenver.edu.

Erin L Chaussee (EL)

Department of Biostatistics and Informatics, University of Colorado School of Public Health, Aurora, CO, USA.
Adult and Child Consortium for Outcomes Research and Delivery Science (ACCORDS), University of Colorado School of Medicine, Aurora, CO, USA.

Elizabeth Juarez-Colunga (E)

Department of Biostatistics and Informatics, University of Colorado School of Public Health, Aurora, CO, USA.
Adult and Child Consortium for Outcomes Research and Delivery Science (ACCORDS), University of Colorado School of Medicine, Aurora, CO, USA.

Adam G Tsai (AG)

Kaiser Permanente, Denver, CO, USA.

Sean J Iwamoto (SJ)

Division of Endocrinology, Metabolism and Diabetes, University of Colorado School of Medicine, Aurora, CO, USA.
Division of Endocrinology, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO, USA.

Rebecca B Speer (RB)

Denver Health Medical Center, Denver, CO, USA.

Hilde Heyn (H)

Denver Health Medical Center, Denver, CO, USA.

Elizabeth H Kealey (EH)

Anschutz Health and Wellness Center, University of Colorado School of Medicine, Aurora, CO, USA.

Daniel H Bessesen (DH)

Division of Endocrinology, Metabolism and Diabetes, University of Colorado School of Medicine, Aurora, CO, USA.
Denver Health Medical Center, Denver, CO, USA.
Anschutz Health and Wellness Center, University of Colorado School of Medicine, Aurora, CO, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH